scholarly journals PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

2020 ◽  
Vol 12 ◽  
pp. 175883592096236
Author(s):  
Liu Jin ◽  
Weiling Gu ◽  
Xueqin Li ◽  
Liang Xie ◽  
Linhong Wang ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Malignant Pleural Mesothelioma ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
The Cancer Genome Atlas ◽  
Cochrane Library ◽  
Pleural Mesothelioma ◽  
Significant Prognostic Factor ◽  
Tcga Dataset

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset. Results: In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28–1.83, p < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82–1.39, p = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16–8.64, p < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136–3.769, p = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572–2.539, p = 0.624), which was in accordance with the results of the meta-analysis. Conclusion: A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.

scholarly journals The Clinicopathological and Prognostic Significance of SOX9 Expression in Gastric Cancer: Meta-Analysis and TCGA Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Guo Zu ◽  
Jiacheng Gao ◽  
Tingting Zhou
Keyword(s):  
Gastric Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Tnm Stage ◽  
The Cancer Genome Atlas ◽  
Depth Of Invasion ◽  
Sox9 Expression ◽  
Potential Prognostic Factor ◽  
Clinicopathological Significance ◽  
Tcga Dataset

BackgroundThe clinicopathological and prognostic significance of SRY-box transcription factor 9 (SOX9) expression in gastric cancer (GC) patients is still controversial. Our aim is to investigate the clinicopathological and prognostic value of SOX9 expression in GC patients.MethodsA systemic literature search and meta-analysis were used to evaluate the clinicopathological significance and overall survival (OS) of SOX9 expression in GC patients. The Cancer Genome Atlas (TCGA) dataset was used to investigate the relationship between SOX9 expression and OS of stomach adenocarcinoma (STAD) patients.ResultsA total of 11 articles involving 3,060 GC patients were included. In GC patients, the SOX9 expression was not associated with age [odds ratio (OR) = 0.743, 95% CI = 0.507–1.089, p = 0.128], sex (OR = 0.794, 95% CI = 0.605–1.042, p = 0.097), differentiation (OR = 0.728, 95% CI = 0.475–1.115, p = 0.144), and lymph node metastasis (OR = 1.031, 95% CI = 0.793–1.340, p = 0.820). SOX9 expression was associated with depth of invasion (OR = 0.348, 95% CI = 0.247–0.489, p = 0.000) and TNM stage (OR = 0.428, 95% CI = 0.308–0.595, p = 0.000). The 1-year OS (OR = 1.507, 95% CI = 1.167–1.945, p = 0.002), 3-year OS (OR = 1.482, 95% CI = 1.189–1.847, p = 0.000), and 5-year OS (OR = 1.487, 95% CI = 1.187–1.862, p = 0.001) were significantly shorter in GC patients with high SOX9 expression. TCGA analysis showed that SOX9 was upregulated in STAD patients compared with that in normal patients (p &lt; 0.001), and the OS of STAD patients with a high expression of SOX9 is poorer than that in patients with low expression of SOX9, but the statistical difference is not obvious (p = 0.31).ConclusionSOX9 expression was associated with the depth of tumor invasion, TNM stage, and poor OS of GC patients. SOX9 may be a potential prognostic factor for GC patients but needs further study.Systematic Review RegistrationPROSPERO, ID NUMBER 275712.

Sub-staging specific differences in recurrence-free, progression-free and cancer-specific survival for patients with T1 bladder cancer: a systematic review and meta-analysis

2020 ◽  
Author(s):  
GuanQiu Chen ◽  
Tao Yang ◽  
Pu Zhang ◽  
Meng-Zhao Zhang ◽  
Bo Yang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Significance ◽  
Treatment Strategies ◽  
Progression Free Survival ◽  
Staging System ◽  
Cochrane Library ◽  
Significant Prognostic Factor ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Significant Difference

Abstract Background: The efficiency of the T1 sub-staging system on categorizing bladder cancer (BC) patients into subgroups with different clinical outcomes was unclear. We summarized relevant evidences, including recurrence-free survival (RFS), progression-free survival (PFS) and cancer-specific survival (CSS), to analyze the prognostic significance of T1 sub-stage.Methods: Systematic literature searches of MEDLINE, EMBASE and the Cochrane Library were performed. We pooled data on recurrence, progression, and CSS from 35 studies.Results: The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) indicated the difference in RFS between T1a sub-stage and T1b sub-stage (HR1.28, 95%CI 1.14-1.43). The significant difference was observed in PFS between the two arms (HR 2.18, 95%CI 1.95-2.44). Worse CSS was found in T1b patients than T1a patients (HR 1.45, 95%CI 1.28-1.64).Conclusions: T1 sub-staging system based on the invasion depth into muscularis mucosae (MM) can be a significant prognostic factor for RFS, PFS, and CSS of patients with T1-BC. Urologists and pathologists are encouraged to work together to give a precise sub-stage classification of T1-BC, and T1 sub-staging system should be a routine part of any histopathological report when possible. Different treatment strategies need to be developed for both T1a-BC and T1b-BC.

scholarly journals Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (28) ◽  
pp. 46425-46435 ◽  
Author(s):  
Long Tian ◽  
Rujun Zeng ◽  
Xin Wang ◽  
Cheng Shen ◽  
Yutian Lai ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Pleural Mesothelioma

scholarly journals The Prognostic Roles and Clinical Features of CD44v9 in Human Solid Cancers—A Meta-Analysis

2020 ◽  
Author(s):  
Yuanxiu Deng ◽  
Jie Wang ◽  
Shenhui Ji ◽  
Lu Huang ◽  
Meijiang Feng
Keyword(s):  
Clinical Features ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
High Expression ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Diagnosis And Prognosis

Abstract Background: CD44 is the primary receptor for hyaluronic acid and serves as a marker for cancer stem cells. CD44v9 is one of CD44’s variants and takes part in cancer’s growth and metastasis. However, the prognostic roles and clinical features of CD44v9 in cancers remain unclear. Therefore, we conducted this meta-analysis to summarize the prognostic significance and clinical features of CD44v9 in human solid cancers.Methods: we systematically searched all of related studies in PubMed, the Web of Science, Embase and Cochrane library up to June 2020. We analyzed the pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) to assess the prognostic functions and clinical features of CD44v9 in various human solid cancers.Results: In this meta-analysis, we included 1705 cancer patients among 12 studies. Results indicated that high expression of CD44v9 was significantly related to poorer overall survival (OS) (HR=1.60, 95%CI 1.28-1.99, P<0.0001), recurrence-free survival/progression-free survival/disease-free survival (RFS/PFS/DFS).( HR=1.81, 95%CI 1.16-2.84, P=0.009) and disease-specific survival/cancer-specific survival (DSS/CSS) (HR=2.93, 95%CI 1.69-5.10, P<0.001). At the same time, we also found that high expression of CD44v9 increased the possibility of lymphoid infiltrates (OR=1.59, 95%CI 1.16-2.20, P=0.005), vascular invasion (OR=1.57, 95%CI 1.11-2.22, P=0.010) and higher TNM stage (OR=1.63, 95%CI 1.19-2.23, P=0.002).Conclusion: Our results demonstrate that CD44v9 overexpression is associated with worse OS, RFS/PFS/CFS and DSS/CSS in patients with solid cancers, which might be a biomarker in the diagnosis and prognosis of cancers in the future.

scholarly journals Overexpression of lncRNA SNGH3 Predicts Unfavorable Prognosis and Clinical Outcomes in Human Cancers: Evidence from a Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Yaofei Jiang ◽  
Lulu Le
Keyword(s):  
Clinical Outcomes ◽  
Histological Grade ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
The Cancer Genome Atlas ◽  
Cochrane Library ◽  
Cancer Type ◽  
Free Survival ◽  
Human Cancers ◽  
Tcga Dataset

Long noncoding RNAs (lncRNAs) have been confirmed to play a crucial role in human disease, especially in tumor development and progression. Small nucleolar RNA host gene (SNHG3), a newly identified lncRNA, has been found dysregulated in various cancers. Nevertheless, the results remain controversial. Thus, we aim to analyze the comprehensive data to elaborate the association between SNHG3 expression and clinical outcomes in multiple cancers. We searched PubMed, Web of Science, Cochrane Library, Embase, and MEDLINE database to identify eligible articles. STATA software was applied to calculate the hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (95% CI) for survival outcomes and clinical parameters, respectively. Besides, the data from The Cancer Genome Atlas (TCGA) dataset was extracted to verify the results in our meta-analysis. There were thirteen studies totaling 919 cancer patients involved in this meta-analysis. The results demonstrated that high SNHG3 expression was significantly associated with poor overall survival (OS) (HR=2.53, 95% CI: 1.94-3.31) in cancers, disease-free survival (DFS) (HR=3.89, 95% CI: 1.34-11.3), and recurrence-free survival (RFS) (HR=2.42, 95% CI: 1.14-5.15) in hepatocellular carcinoma. Analysis stratified by analysis method, sample size, follow-up time, and cancer type further verified the prognostic value of SNHG3. Additionally, patients with high SNHG3 expression tended to have more advanced clinical stage, higher histological grade, earlier distant metastasis, and earlier lymph node metastasis. Excavation of TCGA dataset valuated that SNHG3 was upregulated in various cancers and predicted worse OS and DFS. Overexpressed SNHG3 was strongly associated with poor survival and clinical outcomes in human cancers and therefore can serve as a promising biomarker for predicting patients’ prognosis.

scholarly journals Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Shubo Chen ◽  
Liu Zhang ◽  
Guangyue Yan ◽  
Sijin Cheng ◽  
Abdel Hamid Fathy ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cochrane Library ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Asian People

Background and Aims. Plenty of studies were conducted to explore the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer with contradictory results. This study aims to summarize the prognostic significance of NLR in patients with ovarian cancer. Methods. A literature search in PubMed, Cochrane Library, and Embase was conducted. The endpoints were progression-free survival (PFS) and overall survival (OS). Results. Eleven studies involving a total of 2,892 patients were identified. The results indicated that patients with high NLR had shorter PFS compared to patients with low NLR in ovarian cancer (HR = 1.55, 95% CI = 1.15–2.08, p=0.004, and I2=61%). Similarly, high NLR was related to shorter OS (HR = 1.51, 95% CI = 1.03–2.23, p=0.04, and I2=85%). Moreover, high NLR was significantly associated with shorter PFS when the NLR cut-off was less than 3.3 (p=0.03) or when treatment is operation (p=0.002). In addition, high NLR was distinctly related to worse OS in Asian people (p = 0.04) or operation (p = 0.04). Conclusion. High NLR was associated with shorter PFS and shorter OS in ovarian cancer. NLR is potentially a promising prognostic biomarker in patients with ovarian cancer.

scholarly journals Clinicopathological significance and prognosis of long noncoding RNA SNHG14 expression in human cancers: A Meta-Analysis and bioinformatics analysis

2021 ◽  
Author(s):  
Bin Liu ◽  
Tingting Lu ◽  
Yongfeng Wang ◽  
Yaqiong Chen ◽  
Shixun Ma ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Cox Regression ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Significant Difference ◽  
Pan Cancer

Abstract Background SNGH14 is a recently found long non-coding RNA (lncRNA) with a strong link to cancer. However, it is uncertain if the expression of SNHG14 is linked to the prognosis of individuals with various forms of cancer. We conducted a meta-analysis of the available literature to evaluate the association between SNHG14 and clinicopathological characteristics and patient prognosis Methods The databases PubMed/Medline, Web of Science, Cochrane Library, and Embase were combed for relevant papers published till November 2021. The odds ratio (OR) and 95% confidence interval (CI) were used to analyze dichotomous variables, while the hazard ratio (HR) and 95% CI were employed as a summary statistic for survival outcomes. In addition, the Cancer Genome Atlas TCGA (TCGA) and gene expression omnibus (GEO) database were utilized to investigate SNHG14 differential expression in pan-cancers. Cox regression and Kaplan-Meier analysis were used to investigate the prognostic significance of SNHG14 in pan-cancer. The association between the degree of SNHG14 expression in pan-cancer and immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI) was measured using Spearman correlations. Results A total of 21 studies with 1,080 patients, mainly from China, were included. Our results showed that elevated SNHG14 expression was significantly associated with poor overall survival (OS) (HR = 1.39; 95% CI: 1.06-1.83; P = 0.017). In addition, increased SNHG14 expression was associated with tumor size (OR = 1.60; 95% CI: 1.20-2.14; P = 0.001), TNM staging (OR = 0.54; 95% CI: 0.40-0.71; P <0.001), lymph node metastasis (OR = 1.86; 95% CI: 1.35-2.55; P <0.001), differentiation grade (OR = 1.95; 95% CI: 1.36-2.80; P <0.001), and distant metastasis (OR = 2.44; 95% CI: 1.30 -4.58; P= 0.005). However, there was no significant difference in age (OR = 1.02; 95% CI: 0.77-1.33; P = 0.863) and gender (OR = 0.98; 95% CI: 0.72-1.35; P = 0.915). Conclusion This study revealed that overexpression of SNGH14 is associated with low OS rate and clinicopathological characteristics. SNGH14 can be considered as a new tumor marker that aids in early tumor diagnosis, thus improving the prognosis of patients.

Sign in / Sign up

Export Citation Format

Share Document